The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron PharmaceuticalsZacks Investment Research • 03/07/25
Jazz Offers to Buy Chimerix for $935M to Boost Oncology PortfolioZacks Investment Research • 03/06/25
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZZacks Investment Research • 03/06/25
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,Zacks Investment Research • 03/05/25
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioGlobeNewsWire • 03/05/25
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?Zacks Investment Research • 03/03/25
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?Zacks Investment Research • 02/28/25
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/26/25
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/25/25
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial GuidancePRNewsWire • 02/25/25
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care ConferencePRNewsWire • 02/20/25
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 02/20/25
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025PRNewsWire • 02/11/25